KOLINPHARMA® signs an agreement with ASTAREAL® AB for distribution in the Asian market
![](/46/pdcnewsitem/12/48/49/25%2010%2022.jpg)
KOLINPHARMA® signs an agreement with ASTAREAL® AB for distribution in the Asian market
KOLINPHARMA® signs an important three-year agreement with the multinational ASTAREAL® AB for distribution of products in Mainland China, Hong Kong, Macau, and Taiwan.
The agreement, based on the Cross Boarder Ecommerce Law which entered into force in 2019, also provides that Kolinpharma® and AstaReal® undertake to make all the investments necessary for the setup of the e-commerce platforms and social media according to a digital marketing plan and a long-term strategy defined between the management of Kolinpharma® and the local skills of the headquarters team of Shangai by AstaReal®.
Rita Paola Petrelli, President of KOLINPHARMA®, commented: “We are proud to have sealed this very important partnership with the Swedish multinational, crucial for Kolinpharma's internationalization process. This agreement will allow us to initiate significant commercial development in a market with great potential such as the Asian one, that in China was worth 114.4 bi...
KOLINPHARMA® signs an important three-year agreement with the multinational ASTAREAL® AB for distribution of products in Mainland China, Hong Kong, Macau, and Taiwan.
The agreement, based on the Cross Boarder Ecommerce Law which entered into force in 2019, also provides that Kolinpharma® and AstaReal® undertake to make all the investments necessary for the setup of the e-commerce platforms and social media according to a digital marketing plan and a long-term strategy defined between the management of Kolinpharma® and the local skills of the headquarters team of Shangai by AstaReal®.
Rita Paola Petrelli, President of KOLINPHARMA®, commented: “We are proud to have sealed this very important partnership with the Swedish multinational, crucial for Kolinpharma's internationalization process. This agreement will allow us to initiate significant commercial development in a market with great potential such as the Asian one, that in China was worth 114.4 billion CNY in 2014 and is estimated will reach 328.2 billion CNY (47 billion euros) in 2023."
![Kolinpharma](https://www.cphi-online.com/c286574th_S-comp286574.jpg)
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance